Takeda Pharmaceutical Company Limited (TYO:4502)
Japan · Delayed Price · Currency is JPY 5,760.00
-17.00 (-0.29%)
Sep 9, 2026, 9:00 AM JST
TYO:4502 Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 9,197,330 | 8,948,061 | 6,749,675 | 6,564,378 | 6,762,204 | 5,423,454 | |
Market Cap Growth | 28.73% | 32.57% | 2.82% | -2.93% | 24.68% | -12.95% |
Enterprise Value | 14,273,836 | 13,716,236 | 11,687,795 | 11,482,982 | 10,868,028 | 9,054,481 |
Last Close Price | 5760.00 | 5664.00 | 4239.70 | 3842.61 | 3833.08 | 2945.78 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | - | - | 62.54 | 45.57 | 21.33 | 23.57 |
Forward PE | 40.41 | 35.25 | 32.41 | 31.46 | 21.61 | 14.12 |
PS Ratio | 1.99 | 1.99 | 1.47 | 1.54 | 1.68 | 1.52 |
PB Ratio | 1.22 | 1.20 | 0.97 | 0.90 | 1.06 | 0.95 |
P/FCF Ratio | 11.92 | 10.34 | 7.88 | 12.14 | 8.08 | 5.42 |
P/OCF Ratio | 9.64 | 8.59 | 6.39 | 9.16 | 6.92 | 4.83 |
PEG Ratio | 8.33 | 1.52 | 4.53 | 19.26 | 2.83 | 4.76 |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 3.09 | 3.04 | 2.55 | 2.69 | 2.70 | 2.54 |
EV/EBITDA Ratio | 10.99 | 11.10 | 9.48 | 9.33 | 8.46 | 7.65 |
EV/EBIT Ratio | 22.36 | 22.57 | 20.76 | 22.85 | 17.54 | 15.09 |
EV/FCF Ratio | 18.50 | 15.85 | 13.65 | 21.23 | 12.99 | 9.06 |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.73 | 0.74 | 0.73 | 0.75 | 0.77 | 0.85 |
Debt / EBITDA Ratio | 4.26 | 4.26 | 3.96 | 4.44 | 3.79 | 4.07 |
Debt / FCF Ratio | 7.17 | 6.33 | 5.94 | 10.10 | 5.81 | 4.81 |
Net Debt / Equity Ratio | 0.67 | 0.66 | 0.68 | 0.69 | 0.68 | 0.70 |
Net Debt / EBITDA Ratio | 4.06 | 3.95 | 3.81 | 4.07 | 3.37 | 3.35 |
Net Debt / FCF Ratio | 6.58 | 5.64 | 5.49 | 9.25 | 5.17 | 3.96 |
Asset Turnover | 0.31 | 0.30 | 0.31 | 0.29 | 0.30 | 0.27 |
Inventory Turnover | 1.22 | 1.24 | 1.30 | 1.30 | 1.36 | 1.40 |
Quick Ratio | 0.51 | 0.52 | 0.44 | 0.50 | 0.49 | 0.73 |
Current Ratio | 1.14 | 1.09 | 1.01 | 1.11 | 0.97 | 1.21 |
Return on Equity (ROE) | -2.26% | -2.12% | 1.52% | 2.12% | 5.27% | 4.24% |
Return on Assets (ROA) | 2.69% | 2.55% | 2.40% | 2.16% | 2.85% | 2.88% |
Return on Invested Capital (ROIC) | 5.13% | 5.08% | 2.91% | 4.38% | 5.15% | 4.82% |
Return on Capital Employed (ROCE) | 5.00% | 4.80% | 4.80% | 3.90% | 5.40% | 5.40% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 8, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | -1.78% | -1.70% | 1.60% | 2.20% | 4.69% | 4.24% |
FCF Yield | 8.39% | 9.67% | 12.69% | 8.24% | 12.37% | 18.44% |
Dividend Yield | 3.45% | 3.53% | 4.62% | 4.89% | 4.70% | 6.11% |
Payout Ratio | - | - | 280.28% | 199.34% | 88.14% | 123.30% |
Buyback Yield / Dilution | 1.64% | 1.88% | -1.58% | -0.67% | 0.46% | -0.23% |
Total Shareholder Return | 5.09% | 5.42% | 3.04% | 4.23% | 5.16% | 5.88% |